San Francisco-based startup Orchid Health "screens embryos for thousands of potential future illnesses," reports the Washington Post, calling it "the first company to say it can sequence an embryo's entire genome of 3 billion base pairs."
It uses as few as five cells from an embryo to test for more than 1,200 of these uncommon single-gene-derived, or monogenic, conditions. The company also applies custom-built algorithms to produce what are known as polygenic risk scores, which are designed to measure a future child's genetic propensity for developing complex ailments later in life, such as bipolar disorder, cancer, Alzheimer's disease, obesity and schizophrenia. Orchid, [founder Noor] Siddiqui said in a tweet, is ushering in "a generation that gets to be genetically blessed and avoid disease." Right now, at $2,500 per embryo-screening on top of the average $20,000 for a single cycle of IVF, Siddiqui's social network in Silicon Valley and other tech hubs is an ideal target market... ...
[ Read it >> ]
0 Replies